Halo Pharmaceutical

Halo Pharma is a North American contract development and manufacturing organization serving pharmaceutical innovators, generic drug companies, and over-the-counter product owners. With facilities in Whippany, New Jersey, and Mirabel, Quebec, the company supports small-molecule medicines from early development through commercial production, emphasizing safety, quality, and reliable project delivery.

Its services include formulation development, analytical method development and testing, validation, stability studies, clinical supplies, technology transfer, scale-up, and commercial manufacturing. Halo also offers packaging, order fulfillment, distribution, and demand management. Its dosage-form capabilities include tablets, capsules, powders, granules, oral liquids, creams, ointments, gels, lotions, suppositories, and specialty formats such as modified-release products, stickpacks, mini-tablets, orally disintegrating tablets, controlled substances, and fixed-dose combinations. Sterile vial, prefilled syringe, and cartridge capabilities are planned for 2026.

Halo’s sites support non-GMP and cGMP work, including clinical and registration batches. The company reports regulatory approvals and relationships supporting access to key international markets. Halo Pharma is part of the Noramco Group, alongside Noramco and Purisys, offering customers a broader North American supply-chain option.